US FDA approves Opdivo, Cabometyx combo for advanced renal cell carcinoma
The US Food and Drug Administration (FDA) has approved the combination of Bristol Myers Squibb’ Opdivo (nivolumab) and Exelixis’ Cabometyx (cabozantinib) as a first line therapy for advanced renal cell carcinoma (RCC), a type of kidney cancer. As per the FDA approval, Opdivo 240mg has to be injected intravenously every two weeks or 480mg every […]